全文获取类型
收费全文 | 21243篇 |
免费 | 1753篇 |
国内免费 | 42篇 |
专业分类
耳鼻咽喉 | 139篇 |
儿科学 | 795篇 |
妇产科学 | 570篇 |
基础医学 | 2727篇 |
口腔科学 | 276篇 |
临床医学 | 2394篇 |
内科学 | 4108篇 |
皮肤病学 | 332篇 |
神经病学 | 2268篇 |
特种医学 | 392篇 |
外国民族医学 | 5篇 |
外科学 | 2369篇 |
综合类 | 254篇 |
一般理论 | 67篇 |
预防医学 | 3012篇 |
眼科学 | 286篇 |
药学 | 1463篇 |
1篇 | |
中国医学 | 43篇 |
肿瘤学 | 1537篇 |
出版年
2024年 | 45篇 |
2023年 | 296篇 |
2022年 | 516篇 |
2021年 | 984篇 |
2020年 | 581篇 |
2019年 | 822篇 |
2018年 | 920篇 |
2017年 | 664篇 |
2016年 | 694篇 |
2015年 | 755篇 |
2014年 | 984篇 |
2013年 | 1292篇 |
2012年 | 1788篇 |
2011年 | 1802篇 |
2010年 | 932篇 |
2009年 | 769篇 |
2008年 | 1296篇 |
2007年 | 1376篇 |
2006年 | 1116篇 |
2005年 | 1041篇 |
2004年 | 962篇 |
2003年 | 867篇 |
2002年 | 644篇 |
2001年 | 149篇 |
2000年 | 121篇 |
1999年 | 125篇 |
1998年 | 141篇 |
1997年 | 103篇 |
1996年 | 64篇 |
1995年 | 74篇 |
1994年 | 60篇 |
1993年 | 57篇 |
1992年 | 65篇 |
1991年 | 49篇 |
1990年 | 71篇 |
1989年 | 57篇 |
1988年 | 49篇 |
1987年 | 44篇 |
1986年 | 37篇 |
1985年 | 45篇 |
1984年 | 36篇 |
1982年 | 30篇 |
1981年 | 39篇 |
1980年 | 34篇 |
1979年 | 43篇 |
1977年 | 29篇 |
1974年 | 29篇 |
1973年 | 28篇 |
1972年 | 31篇 |
1971年 | 30篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
71.
Epidemiologic evidence for early onset of mental disorders and higher risk of drug abuse in young adults 总被引:8,自引:0,他引:8
K A Christie J D Burke D A Regier D S Rae J H Boyd B Z Locke 《The American journal of psychiatry》1988,145(8):971-975
Data from the National Institute of Mental Health (NIMH) Epidemiologic Catchment Area Program, an epidemiologic survey of five communities, showed that four major disorders commonly begin in late adolescence or young adulthood. The median age at onset for anxiety disorders is 15 years; for major depressive episode, 24 years; for drug abuse or dependence, 19 years; and for alcohol abuse or dependence, 21 years. Findings also suggest that for respondents 18-30 years old, having a major depressive episode or anxiety disorder doubles the risk for later drug abuse or dependence. 相似文献
72.
·病例简介:患者,男,22岁。因鼻部(见图1)、左侧肩部(见图2)、右侧背部及左侧大腿部皮疹就诊。既往身体健康,近期有到加利福尼亚中央谷旅游史,否认异地长期居住史,近期无服药史。患者无发热,无夜间盗汗,无寒战。既往诊断为耐甲氧西林金黄色葡萄球菌(MRSA)感染,接受甲氧苄氨嘧啶 相似文献
73.
Christian Otte Maryann Lenoci Thomas Metzler Rachel Yehuda Charles R Marmar Thomas C Neylan 《Neuropsychopharmacology》2007,61(8):952-956
BACKGROUND: Metyrapone blocks cortisol synthesis which results in removal of negative feedback, a stimulation of hypothalamic corticotropin releasing factor (CRF) and a reduction in delta sleep. We previously reported a diminished delta sleep and hypothalamic-pituitary-adrenal (HPA) response to metyrapone in men with post-traumatic stress disorder (PTSD). In this study, we aimed to extend these findings to women. METHODS: Three nights of polysomnography were obtained in 17 women with PTSD and 16 controls. On day 3, metyrapone was administered throughout the day up until bedtime. Plasma adrenocorticotropic hormone (ACTH), cortisol, and 11-deoxycortisol were obtained the morning following sleep recordings the day before and after metyrapone administration. RESULTS: There were no significant between-group differences in hormone concentration and delta sleep at baseline. Relative to controls, women with PTSD had decreased ACTH and delta sleep responses to metyrapone. Decline in delta sleep was associated with the magnitude of increase in ACTH across groups. CONCLUSIONS: Similar to our previous findings in men, the ACTH and sleep electroencephalogram response to metyrapone is attenuated in women with PTSD. These results are consistent with a model of downregulation of CRF receptors in an environment of chronically increased CRF activity or with enhanced negative feedback regulation in PTSD. 相似文献
74.
Botulinum Toxin A in the Treatment of Chromhidrosis 总被引:1,自引:0,他引:1
Wu Jessie M. Mamelak Adam J. MD † Nussbaum Rachel MD † McElgunn Patrick S. J. MD MBA † 《Dermatologic surgery》2005,31(8):963-965
Background. Chromhidrosis is an uncommon disorder characterized by secretion of colored sweat by apocrine glands, typically localized to the face or axilla. The current treatments available for chromhidrosis are time consuming and frequently ineffective.
Objective. Our purpose is to demonstrate a novel approach to the treatment of apocrine chromhidrosis.
Methods. We report a case of apocrine chromhidrosis successfully treated with botulinum toxin A (BTX-A; Botox).
Results. BTX-A therapy successfully controlled facial chromhidrosis, and the effects were visible at 19 weeks post-treatment. The therapeutic benefits may be attributed to its inhibitory effects on cholinergic stimulation, adrenergic stimulation, and substance P release, although further studies are necessary to elucidate the precise mechanism of action.
Conclusion. This report demonstrates a new therapeutic approach to patients suffering from chromhidrosis. 相似文献
Objective. Our purpose is to demonstrate a novel approach to the treatment of apocrine chromhidrosis.
Methods. We report a case of apocrine chromhidrosis successfully treated with botulinum toxin A (BTX-A; Botox).
Results. BTX-A therapy successfully controlled facial chromhidrosis, and the effects were visible at 19 weeks post-treatment. The therapeutic benefits may be attributed to its inhibitory effects on cholinergic stimulation, adrenergic stimulation, and substance P release, although further studies are necessary to elucidate the precise mechanism of action.
Conclusion. This report demonstrates a new therapeutic approach to patients suffering from chromhidrosis. 相似文献
75.
76.
Supha K Arthurs Albert J Eid Rachel A Pedersen Ross A Dierkhising Walter K Kremers Robin Patel Raymund R Razonable 《Liver transplantation》2007,13(12):1703-1709
Clinical practice guidelines recommend antiviral prophylaxis to cytomegalovirus (CMV) donor-positive/recipient-negative (D+/R-) liver transplant recipients. We assessed the outcome of this strategy by determining the incidence, clinical features, and risk factors of CMV disease among CMV D+/R- liver transplant recipients who received antiviral prophylaxis. Sixty-seven CMV D+/R- liver transplant recipients (mean age+/-standard deviation: 49.5+/-11.4 years; 75% male) received oral ganciclovir [n=9 (13%)] or valganciclovir [n=58 (87%)] prophylaxis for a median duration of 92 days (interquartile range: 91-100). No breakthrough CMV disease was observed during antiviral prophylaxis. However, primary CMV disease was observed in 2%, 25%, 27%, 27%, and 29% of patients at 1, 3, 6, 12, and 24 months, respectively, after antiviral prophylaxis was stopped. The incidence of delayed-onset primary CMV disease was similar between those who received oral ganciclovir and valganciclovir. Nine (47%) patients had CMV syndrome, 8 (42%) had gastrointestinal CMV disease, and 2 (11%) had CMV hepatitis. Female patients (P=0.01) and younger age at transplant (P=0.03) were associated with an increased risk, whereas diabetes mellitus (P<0.001) was significantly associated with a lower risk of delayed-onset primary CMV disease. Allograft loss or mortality occurred in 8 (12%) patients during the median follow-up period of 3.31 (range: 0.8-5.9) years. No significant association was observed between CMV disease and patient and allograft survival. In conclusion, CMV disease remains a common complication in CMV D+/R- liver transplant patients during the contemporary era of antiviral prophylaxis. Female patients and younger patients are at increased risk of delayed-onset primary CMV disease. 相似文献
77.
Vivek N Ahya Alden M Doyle James D Mendez David A Lipson Jason D Christie Emily A Blumberg Alberto Pochettino Linda Nelson Roy D Bloom Robert M Kotloff 《The Journal of heart and lung transplantation》2005,24(7):932-935
Chronic rejection is the major hurdle to long-term survival after lung transplantation. Endobronchial infection with Pseudomonas aeruginosa is common in patients with chronic rejection and this may further contribute to deterioration of the allograft. Inhaled tobramycin is commonly used to treat P aeruginosa airways infection in patients with cystic fibrosis. The safety of inhaled tobramycin in transplant recipients, however, has not been established. We describe the first report of a lung transplant recipient who developed renal failure and vestibular injury after receiving inhaled tobramycin. We review the literature regarding the safety of inhaled tobramycin and discuss potential mechanisms that may promote systemic toxicity in transplant recipients. 相似文献
78.
79.
80.